The ITN is currently inviting proposals for novel clinical trials with the aim of inducing tolerance in patients who receive gene/protein-replacement (e.g. hemophilia, Gaucher’s disease) or other exogenous protein therapy, in which the patients are at risk for developing an immune response to the biologic agent. The ideal proposal would have a testable mechanism of tolerance induction and a strategy for assays investigating this mechanism.
Full details are included in the RFP. Proposals should be submitted to Philip Bernstein, Executive Director of Strategic Review and Planning (pbernstein@immunetolerance.org), by November 30th, 2015.